Implementing changes in clinical practice to improve the management of Crohn's disease

Journal of Crohn's and Colitis

Volumn 6, Issue SUPPL.2, 2012, Pages

  Panaccione, Remo ^a   Hibi, Toshifumi ^b   Peyrin Biroulet, Laurent ^c   Schreiber, Stefan ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CHU NANCY BRABOIS   (France)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

Corticosteroids; Crohn's disease; Immunomodulators; Optimized monitoring; Treatment optimization

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COLON MUCOSA; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE ACTIVITY; DOUBLE BALLOON ENTEROSCOPY; EARLY INTERVENTION; ENDOSCOPY; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HUMAN; IMMUNOMODULATION; JAPAN; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REMISSION; SYMPTOMATOLOGY; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859070472     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/S1873-9946(12)60503-0     Document Type: Article

References (47)

1. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M Development of the Crohn's Disease Digestive Damage Score, the Lémann Score. Inflamm Bowel Dis 2011, 17:1415-1422.
2. Ghosh S, D'Haens G, Feagan BG, Silverberg MS, Szigethy EM What do changes in inflammatory bowel disease management mean for our patients?. J Crohn's Colitis 2012, 6(Suppl 2):S243-S249.
3. Walsh A, Mabee J, Trivedi K Inflammatory bowel disease. Prim Care 2011, 38:415-432.
4. Colombel J-F, Rutgeerts P, Sandborn WJ, Camez A, Pollack PF, Chen N, Yang M, Chao J, Mulani PM J Crohn's Colitis 2010, 4:S11. (abstract OP31 at ECCO 2010).
5. Colombel JF, Rutgeerts P, Sandborn WJ, Yang M, Lomax KG, Pollack PF, Thakkar R, Camez A, Chen N, Mulani PM, Chaoet J Deep remission predicts long-term outcomes for adalimumab-treated patients with Crohn's disease: data from EXTEND. Gut 2010, 59(Suppl 3):A80. OP371 at UEGW2010.
6. Lichtenstein GR, Hanauer SB, Sandborn WJ Management of Crohn's disease in adults. Am J Gastroenterol 2009, 104:465-483.
7. van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkuhn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, Travis S, Stange E The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010, 4:7-27.
8. American Gastroenterological Association Clinical Practice Committee American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 2003, 125:1503-1507.
9. Dignass A, van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollon F, Hommes DW, Michetti P, O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010, 4:28-62.
10. Ferrante M, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel J-F, Panaccione R Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme. J Crohns Colitis 2012, 6:11-31.
11. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, Singleton JW National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterol 1979, 77:847-869.
12. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterol 1990, 98:811-818.
13. Benchimol EI, Seow CH, Steinhart AH, Griffiths AM Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008, CD006792.
14. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008, CD000296.
15. Munkholm P, Langholz E, Davidsen M, Binder V Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35:360-362.
16. Singleton JW, Law DH, Kelley ML, Mekhjian HS, Sturdevant RA National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterol 1979, 77:870-882.
17. Benchimol EI, Seow CH, Otley AR, Steinhart AH Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, CD002913.
18. Brignola C, De Simone G, Belloli C, Iannone P, Belluzzi A, Gionchetti P, Campieri M, Barbara L Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994, 8:465-468.
19. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54:237-241.
20. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010, 59:1200-1206.
21. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119:895-902.
22. Sans M, López-San Román A, Esteve M, Bermejo F, García-Sánchez V, Torres Y Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterol 2011, 140(Suppl 1):S109.
23. Mate-Jiménez J, Hermida C, Cantero-Perona J, Moreno-Otero R 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000, 12:1227-1233.
24. Lémann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Modigliani R, Bouhnik Y Groupe D'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterol 2005, 128:1812-1818.
25. Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Cosnes J, Lemann M, Groupe D'Etude Thérapeutique Des Affections Inflammatoires Du Tube Digestif (GETAID) Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009, 7:80-85.
26. Nachury M, Lemann M, Cosnes J, Gomet J-M, Beaugerie L, Allez M, Gendre J-P, Modigliani R Efficacy of a Second Course of Azathioprine in Patients with Crohn's Disease Relapsing After Azathioprine Withdrawal. Gastroenterol 2003, 124:A-522. (Abstract T1381).
27. Bouguen G, Peyrin-Biroulet L Surgery for adult Crohn's disease: what is the actual risk?. Gut 2011, 60:117-181.
28. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ Early Crohn disease: a proposed definition for use in disease-modification trials. Gut 2010, 59:141-147.
29. Kirwan JR Conceptual Issues in Scoring Radiographic Progression in RA. J Rheumatol 1999, 26:720-725.
30. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132(1):52-65.
31. Schreiber S., Reinisch W., Colombel J., Sandborn W.J., Hommes D, Li J, Kent JD, Pollack PF Early Crohn's disease shows high levels of remission to therapy with adalimumab: Sub-analysis of CHARM. Gastroenterology 2007, 132(4 Suppl 1):A147. (abstract 985).
32. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkuhn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
33. Baert F, Moortgat L, van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
34. Colombel J-F, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P, for the SONIC Study Group Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
35. Sandborn WJ, Panaccione R, Thakkar R, Lomax KG, Chen N, Mulani PM, Chao J, Yang M Duration of Crohn's Disease Affects Mucosal Healing in Adalimumab-Treated Patients: Results From EXTEND. J Crohn's Colitis 2010, 4:S36. (abstract PO69 at ECCO 2010).
36. Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PDR, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel J-F, Travis S, Sandborn WJ Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Consensus. Am J Gastroenterol 2012, in press.
37. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008, 359:1565-1576.
38. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a singleblind randomised controlled trial. Lancet 2004, 364:263-269.
39. Hommes D, Colombel J.-F, Emery P, Greco M, Sandborn WJ Changing Crohn's disease management: Need for new goals and indices to prevent disability and improve quality of life. J Crohn's Colitis 2012, 6(Suppl 2):S224-S234.
40. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004, 60:505-512.
41. Rimola J, Ordás I, Rodriguez S, García-Bosch O, Aceituno M, Llach J, Ayuso C, Ricart E, Panés J Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011, 17:1759-1768.
42. Tamboli CP, Doman DB, Patel A Current and future role of biomarkers in Crohn's disease risk assessment and treatment. Clin Exp Gastroenterol 2011, 4:127-140.
43. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:707-712.
44. Judd TA, Day AS, Lemberg DA, Turner D, Leach ST Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol 2011, 26:1493-1499.
45. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000, 119:15-22.
46. Schmidt C, Giese T, Hermann E, Zeuzem S, Meuer SC, Stallmach A Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis 2007, 13:65-70.
47. Jurgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, Ballet V, Noman M, Hoffman I, van Assche G, Rutgeerts PJ, van Steen K, Vermeire S Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011, 9:421-427.